Aduhelm OK 'bit­ter­sweet' for ALS ad­vo­cates; Con­trast­ing Covid-19 vac­cine read­outs; GSK joins TIG­IT bat­tle; and more

Yesterday
Weekly

FDA's con­tro­ver­sial Aduhelm de­ci­sion leaves ALS pa­tients feel­ing spurned

2 days ago
Pharma
In Focus

Biotech founder placed on leave as $400M Alzheimer's start­up idea comes un­der scruti­ny

2 days ago
People
R&D

Sen. Manchin to Biden: Don't nom­i­nate Wood­cock for FDA com­mis­sion­er

2 days ago
FDA+

Bris­tol My­ers breaks the bank on Ei­sai's fo­late re­cep­tor ADC drug, lay­ing out more than $3B+ for rights

3 days ago
Deals

Biden in­vests $3B in­to an­tivi­ral de­vel­op­ment for Covid-19

3 days ago
Coronavirus

As it awaits piv­otal re­view of lead drug, Fi­bro­Gen bol­sters its ear­ly pipeline with li­cens­ing deal for galectin pro­gram

3 days ago
Deals

Vi­ral man­u­fac­tur­er Viba­log­ics plots out ex­pan­sion at Ger­man site as US growth plans are un­der­way

3 days ago
Outsourcing
Manufacturing

Sid Mukher­jee's Vor adds clin­i­cal man­u­fac­tur­ing fa­cil­i­ty at ex­ist­ing Boston-area site, beef­ing up for a com­mer­cial push

3 days ago
R&D
Manufacturing

Blue­print Med­i­cines nabs 4th ap­proval in bid to­ward prof­itabil­i­ty

3 days ago
R&D

UP­DAT­ED: Cure­Vac blames vari­ants as a close­ly-watched Covid vac­cine goes down in flames, fail­ing piv­otal study with woe­ful da­ta

4 days ago
R&D

Days af­ter con­tro­ver­sy greet­ed Bio­gen's block­buster Alzheimer's OK, the big biotech con­cedes a set­back on the tau front

4 days ago
R&D

Chi­nese on­col­o­gy spe­cial­ist Zai Lab bro­kers a deal with Macro­Gen­ics for up to 4 bis­pecifics with a mod­est down pay­ment

4 days ago
Deals

Amid slug­gish sales and du­el­ing law­suits, No­var­tis bows out of Am­gen part­ner­ship, slash­es staff

4 days ago
Deals
Pharma

New Alzheimer's drug ap­proval fall­out: Pub­lic Cit­i­zen seeks re­moval of FDA's Wood­cock, Cavaz­zoni and Dunn

4 days ago
FDA+

Michel Sade­lain puts his name and new cell en­gi­neer­ing tech be­hind 'ag­nos­tic' CAR-T start­up chas­ing epi­ge­net­ic anti­gens

5 days ago
Financing
Startups

Mis­sis­sip­pi sues Eli Lil­ly, Sanofi and No­vo over in­sulin prices as in­ter­change­able biosim­i­lars may ar­rive soon

5 days ago
Pharma

Ex­sci­en­tia spends Soft­Bank's cash in bid to edge out AI ri­vals

5 days ago
Deals
AI

UP­DAT­ED: Sage's sec­ond chance at de­pres­sion hits the PhI­II pri­ma­ry, but ques­tions re­main over dura­bil­i­ty, side ef­fects

5 days ago
R&D

UP­DAT­ED: Ex-FDA com­mish Stephen Hahn joins Flag­ship, a ven­ture group that spawned Covid-19 vac­cine mak­er Mod­er­na

6 days ago
People

Bio­gen sig­nals a big PhI­II fail­ure as the lead gene ther­a­py in their $800M Night­star buy­out goes down in flames

6 days ago
R&D

‘You have to get up on the podi­um’: In­com­ing BIO chair Paul Hast­ings on di­ver­si­ty, drug pric­ing and work­ing with the FDA

6 days ago
People

Look­ing be­yond the pan­dem­ic, Mod­er­na ap­points J&J vet­er­an Paul Bur­ton as new CMO

6 days ago
People

Top an­a­lyst maps a rocky road for Ver­tex — un­less they adopt a $10B M&A cam­paign to save the pipeline

6 days ago
Deals
Pharma
1234 Next page Last page